Evidence map›Paper›PMID 28261651›Full record

ArticleOncology and therapy2016

A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study.

Véronique Diéras, Thomas Bachelot, Mario Campone, Nicolas Isambert, Florence Joly, Christophe Le Tourneau, Philippe Cassier, Emmanuelle Bompas, Pierre Fumoleau, Sabine Noal and 4 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01165385 (An Open Label Dose Escalation and Pharmacokinetic Phase I Study With Pazopanib in Combination With Cisplatin), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01165385 phase1completednot on this map

An Open Label Dose Escalation and Pharmacokinetic Phase I Study With Pazopanib in Combination With Cisplatin (CDDP) Every Three Weeks in Patients With Advanced Solid Tumors

TypeinterventionalSponsorUNICANCERRan2010 to 2014Enrolled35ConditionsSolid Tumors, Metastatic CancerArmscisplatin, Pazopanib
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Hydrogen Sulfide Biology and Its Role in Cancer.Molecules (Basel, Switzerland) · 2022
    Review
  2. Article
  3. New advances in targeted gastric cancer treatment.World journal of gastroenterology · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Véronique DiérasDepartment of Medical Oncology, Institut Curie, Saint-Cloud, Paris, France.
Thomas BachelotDepartment of Medical Oncology, Centre Léon Bérard, Lyon, France.
Mario CamponeDepartment of Medical Oncology, Institut de Cancérologie de l'Ouest, Nantes, France.
Nicolas IsambertDepartment of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.
Florence JolyDepartment of Medical Oncology, Centre François Baclesse, Caen, France.
Christophe Le TourneauDepartment of Medical Oncology, Institut Curie, Saint-Cloud, Paris, France.
Philippe CassierDepartment of Medical Oncology, Centre Léon Bérard, Lyon, France.
Emmanuelle BompasDepartment of Medical Oncology, Institut de Cancérologie de l'Ouest, Nantes, France.
Pierre FumoleauDepartment of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.
Sabine NoalDepartment of Medical Oncology, Centre François Baclesse, Caen, France.
Christine OrsiniR&D Department, UNICANCER, Paris, France.
Marta JimenezR&D Department, UNICANCER, Paris, France.
Diane Charlotte ImbsInstitut Claudius Regaud, Inserm, UMR1037 CRCT, Université Toulouse III-Paul Sabatier, Toulouse, France.
Etienne ChatelutInstitut Claudius Regaud, Inserm, UMR1037 CRCT, Université Toulouse III-Paul Sabatier, Toulouse, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTo determine the feasibility, maximum-tolerated dose (MTD), and dose-limiting toxicities (DLT) of pazopanib in combination with cisplatin.

methodsPatients with advanced malignancies were included in a 3 + 3 dose-escalation phase I study. Pazopanib administration started 8 days before the first infusion of cisplatin; some patients were treated according to a reverse sequence (cisplatin first). Five dose levels (DLs) were planned. MTD was based on DLT observed during cycles 1 and 2.

resultsThirty-five patients were enrolled. The MTD was reached at the first DL, (pazopanib 400 mg daily + cisplatin 75 mg/m

conclusionCisplatin and pazopanib could not be administered at their single agent full doses, partly due to a PK interaction between pazopanib and aprepitant.

fundingThis work was funded by GlaxoSmithKline and by the charity Ligue Nationale de Lutte Contre le Cancer. TRIAL REGISTERED: ClinicalTrials.gov identifier, NCT01165385.

Indexed as

AprepitantCisplatinPazopanibPhase I trialSafetySolid tumors

Identifiers

PMID28261651
PMCPMC5315079

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.